We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Accept
Home » Merck KGaA Drops Oral MS Drug Cladribine Following FDA Meeting
Merck KGaA Drops Oral MS Drug Cladribine Following FDA Meeting
June 24, 2011
Merck KGaA is abandoning its approval efforts for its oral multiple sclerosis (MS) drug cladribine after a meeting with the FDA, and it is pulling the drug from markets where it is already approved.